Twist Bioscience (NASDAQ:TWST) Stock Price Target Cut by Robert W. Baird

Key Points

• Robert W. Baird cut its Twist Bioscience price target from $187 to $135 but maintained an “outperform” rating; the new target implies 18.19% upside from the prior close.
• Analyst views are mixed: the average rating is “Hold,” with an average price target of $149.82. The stock fell 6.8% in Friday trading.
• Twist beat quarterly estimates, with revenue up 26.7% year over year to $126.6 million and a narrower-than-expected loss. Despite the results, the company remains unprofitable and reports flagged ongoing cost and profitability concerns.

Twist Bioscience (NASDAQ:TWST - Get Free Report) had its price target dropped by equities research analysts at Robert W. Baird from $187.00 to $135.00 in a note issued to investors on Friday, Benzinga reports. The firm presently has an "outperform" rating on the stock. Robert W. Baird's price objective points to a potential upside of 18.19% from the stock's previous close.

Other equities analysts also recently issued research reports about the stock. Piper Sandler lifted their price target on shares of Twist Bioscience from $85.00 to $115.00 and gave the company an "overweight" rating in a report on Wednesday, August 5th. Canaccord Genuity Group set a $150.00 price objective on shares of Twist Bioscience in a research note on Friday. BWS Financial restated a "sell" rating and set a $45.00 price objective on shares of Twist Bioscience in a research report on Friday, September 18th. Leerink Partners lifted their target price on shares of Twist Bioscience from $160.00 to $190.00 and gave the company an "outperform" rating in a research note on Tuesday, September 29th. Finally, Jefferies Financial Group began coverage on shares of Twist Bioscience in a report on Thursday, October 8th. They issued a "hold" rating and a $150.00 target price for the company. Seven analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $149.82.

Twist Bioscience Stock Down 6.8%

TWST stock opened at $114.22 on Friday. Twist Bioscience has a twelve month low of $23.30 and a twelve month high of $219.71. The company has a quick ratio of 2.38, a current ratio of 2.67 and a debt-to-equity ratio of 0.03. The stock has a market cap of $7.16 billion, a P/E ratio of -51.45 and a beta of 2.25. The business's 50-day moving average price is $150.57 and its 200-day moving average price is $92.73.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its earnings results on Thursday, November 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.07. The company had revenue of $126.64 million during the quarter, compared to analyst estimates of $123.55 million. Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. The firm's quarterly revenue was up 26.7% compared to the same quarter last year. On average, equities research analysts forecast that Twist Bioscience will post -2.11 EPS for the current year.

Insiders Place Their Bets

In other Twist Bioscience news, CEO Emily M. Leproust sold 356,546 shares of the company's stock in a transaction that occurred on Thursday, September 17th. The stock was sold at an average price of $157.99, for a total value of $56,330,702.54. Following the completion of the transaction, the chief executive officer directly owned 620,589 shares in the company, valued at $98,046,856.11. This represents a 36.49% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Paula Green sold 10,088 shares of the stock in a transaction that occurred on Friday, October 2nd. The shares were sold at an average price of $188.88, for a total transaction of $1,905,421.44. Following the sale, the senior vice president directly owned 106,632 shares of the company's stock, valued at approximately $20,140,652.16. This trade represents a 8.64% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 495,279 shares of company stock valued at $80,489,387. 3.08% of the stock is owned by company insiders.

Institutional Trading of Twist Bioscience

A number of institutional investors and hedge funds have recently bought and sold shares of TWST. First Trust Advisors LP increased its stake in Twist Bioscience by 3.9% in the 3rd quarter. First Trust Advisors LP now owns 198,259 shares of the company's stock worth $38,312,000 after acquiring an additional 7,380 shares during the last quarter. E Fund Management Hong Kong Co. Ltd. purchased a new stake in shares of Twist Bioscience during the 3rd quarter worth approximately $280,000. Westpac Banking Corp boosted its position in shares of Twist Bioscience by 156.7% during the 3rd quarter. Westpac Banking Corp now owns 15,660 shares of the company's stock valued at $3,026,000 after acquiring an additional 9,560 shares during the last quarter. Private Advisor Group LLC bought a new position in shares of Twist Bioscience during the 3rd quarter valued at approximately $523,000. Finally, Ieq Capital LLC boosted its position in shares of Twist Bioscience by 7.5% during the 3rd quarter. Ieq Capital LLC now owns 54,948 shares of the company's stock valued at $10,618,000 after acquiring an additional 3,839 shares during the last quarter.

Key Stories Impacting Twist Bioscience

Investors following TWST have been watching these stories:

• Positive Sentiment: Fiscal Q4 revenue rose 26.7% year over year to $126.6 million, beating estimates. The loss of $0.32 per share was also narrower than analysts expected and improved from $0.45 a year earlier. Zacks Q4 earnings report
• Positive Sentiment: Twist forecast Q1 fiscal 2027 revenue of $130 million–$132 million, above the $126.3 million consensus estimate. It also reported $59.1 million in fiscal 2026 AI drug-discovery revenue. The Motley Fool analysis
• Negative Sentiment: Despite the quarterly beats, coverage characterized the forward outlook as underwhelming and flagged ongoing cost and profitability concerns. Twist remains loss-making, and this cautious outlook appears to be weighing on the stock. Investor’s Business Daily earnings coverage

About Twist Bioscience

Twist Bioscience Corporation is a biotechnology company that uses a silicon-based platform to manufacture synthetic DNA. Its technology supports the production of many DNA sequences in parallel for research and commercial applications. The company provides synthetic genes, gene fragments and oligonucleotide pools, as well as tools for next-generation sequencing, including target-enrichment products. Through its biopharma business, Twist also offers antibody discovery and related services to support the development of therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.